Price seen as key problem in Guidant/Johnson & Johnson merger prospect
This article was originally published in Clinica
Executive Summary
Rumours over a merger between Johnson & Johnson and Guidant are flying fast and furious after anonymous management members told The New York Times that J&J was offering in excess of $24bn to acquire Guidant.